Endonovo Therapeutics Adds to its Scientific Advisory Board

Endonovo Therapeutics, a commercial-stage developer of non-invasive Electroceutical therapeutic devices, has appointed Peter Novak, M.D., Ph.D., to its Scientific Advisory Board.
 
Endonovo CEO Alan Collier stated, “The Endonovo team is delighted to welcome Dr. Novak to the Scientific Board. Peter’s experience will add significant value to our oversight as we transition to and advance our differentiated development programs in Electroceuticals. We also welcome the insights of Dr. Novak, whose expertise in key areas relating to our programs will inform both our clinical and post-operative strategies.”

Peter Novak, M.D., Ph.D., is the director of the Autonomic Laboratory at the Department of Neurology, Brigham and Women’s Hospital in Boston, Mass. He is a board-certified neurologist and a board-certified autonomic specialist. He is a member of the American Academy of Neurology, American Autonomic Society and the Autonomic Board of United Council for Neurologic Subspecialties.
 
Dr. Novak graduated from medical school in Bratislava, Slovakia, and completed his neurology residency at Ohio State University. He also completed postdoctoral studies focusing on cardiovascular and autonomic research at Charles University (Prague) the University of Montreal, McGill University (Montreal) and the Mayo Clinic. He has special interests in autoimmune, small fiber and autonomic neuropathies, autoimmune, postural orthostatic tachycardia syndrome and multiple system atrophy. He has written over 70 papers and presented at numerous conferences.

“Electroceutical therapy is a fascinating new frontier, and Endonovo has assembled a pipeline that approaches compelling pathways from unique angles,” said Dr. Novak. “There is a major need for therapeutics that improve post-operative recuperation, so I am pleased to join a team that has connected novel science with patient need so clearly.”
 
Endonovo Therapeutics Inc. is a commercial-stage developer of noninvasive wearable Electroceuticals therapeutic devices. The company’s current portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The company’s non-invasive Electroceutical therapeutic device, SofPulse, which uses pulsed short-wave radiofrequency at 27.12 MHz, has been U.S. Food and Drug Administration-cleared and CE marked for the palliative treatment of soft tissue injuries and post-operative pain and edema and has CMS national coverage for the treatment of chronic wounds.
 
The company’s current portfolio of preclinical-stage Electroceuticals therapeutic devices addresses chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The company’s non-invasive, wearable Electroceuticals therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.